Patents by Inventor Clement Rioux
Clement Rioux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100029912Abstract: Fusion proteins comprising an antigen derived from NY-ESO-1 linked to an antigen derived from LAGE-1, which may further comprise carriers, fusion partners, or the like, are provided. Methods for preparing, formulating, and using such fusion proteins are also provided. Such proteins are useful a vaccine components for inducing an immune response against a range of cancer-antigen-bearing cells.Type: ApplicationFiled: July 15, 2009Publication date: February 4, 2010Applicant: GlaxoSmithKline Biologicals SAInventors: Normand Blais, Martine Boyer, Vincent Brichard, Jamila Louahed, Denis Martin, Remi Palmantier, Clement Rioux
-
Publication number: 20090324639Abstract: Methods for making and using therapeutic formulations of Proteosome-based immunoactive compositions are provided. The immunogenic compositions, which include Proteosomes and liposaccharides, may be used to elicit or enhance a nonspecific innate immune response to, for example, treat or prevent infectious disease. In addition, after activating the innate immune system, immunogenic compositions further containing an antigen may be used to elicit a specific adaptive immune response. Furthermore, provided are compositions capable of altering hyperreactive responses or inflammatory immune responses, such as allergic reactions. Such compositions may be used as a prophylactic, or in various clinical settings to treat or prevent infectious disease (such as parasite, fungal, bacterial or viral infections), or to alter inappropriate inflammatory immune responses (such as allergic reactions or asthma).Type: ApplicationFiled: April 28, 2008Publication date: December 31, 2009Applicant: ID BIOMEDICAL CORPORATION OF QUEBECInventors: George H. Lowell, David S. Burt, David Hugh Jones, Joseph J. Zimmermann, Clement Rioux
-
Publication number: 20090318337Abstract: Methods for making and using therapeutic formulations of Proteosome-based immunoactive compositions are provided. The immunogenic compositions, which include Proteosomes and liposaccharides, may be used to elicit or enhance a nonspecific innate immune response to, for example, treat or prevent infectious disease. In addition, after activating the innate immune system, immunogenic compositions further containing an antigen may be used to elicit a specific adaptive immune response. Furthermore, provided are compositions capable of altering hyperreactive responses or inflammatory immune responses, such as allergic reactions. Such compositions may be used as a prophylactic, or in various clinical settings to treat or prevent infectious disease (such as parasite, fungal, bacterial or viral infections), or to alter inappropriate inflammatory immune responses (such as allergic reactions or asthma).Type: ApplicationFiled: October 22, 2004Publication date: December 24, 2009Applicant: ID Biomedical Corporation of QuebecInventors: George H. Lowell, David S. Burt, David Hugh Jones, Joseph J. Zimmermann, Clement Rioux
-
Patent number: 7635482Abstract: Streptococcus proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.Type: GrantFiled: August 29, 2006Date of Patent: December 22, 2009Assignee: ID Biomedical CorporationInventors: Josee Hamel, Bernard R. Brodeur, Isabelle Pineau, Denis Martin, Clement Rioux, Nathalie Charland
-
Publication number: 20090252762Abstract: An adjuvant complex composed of bacterial outer membrane protein proteosomes complexed to bacterial liposaccharide is prepared to contain the component parts under a variety of conditions. The complex can be formulated with antigenic material to form immunogenic compositions, vaccines and immunotherapeutics. An induced immune response includes protective antibodies and/or type 1 cytokines is shown for a variety of protocols.Type: ApplicationFiled: March 30, 2009Publication date: October 8, 2009Applicant: ID BIOMEDICAL CORPORATION OF QUEBECInventors: David S. Burt, George H. Lowell, Gregory L. White, David Jones, Clement Rioux
-
Patent number: 7524509Abstract: An adjuvant complex composed of bacterial outer membrane protein proteosomes complexed to bacterial liposaccharide is prepared to contain the component parts under a variety of conditions. The complex can be formulated with antigenic material to form immunogenic compositions, vaccines and immunotherapeutics. An induced immune response includes protective antibodies and/or type 1 cytokines is shown for a variety of protocols.Type: GrantFiled: March 11, 2002Date of Patent: April 28, 2009Assignee: ID Biomedical Corporation of QuebecInventors: David S. Burt, George H. Lowell, Gregory L. White, David Jones, Clement Rioux
-
Publication number: 20080124337Abstract: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoeae strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.Type: ApplicationFiled: October 30, 2007Publication date: May 29, 2008Applicant: ID BIOMEDICAL CORPORATIONInventors: Bernard R. Brodeur, Denis Martin, Josee Hamel, Clement Rioux
-
Publication number: 20080124353Abstract: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoeae strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.Type: ApplicationFiled: October 30, 2007Publication date: May 29, 2008Applicant: ID BIOMEDICAL CORPORATIONInventors: Bernard R. Brodeur, Denis Martin, Josee Hamel, Clement Rioux
-
Publication number: 20080124351Abstract: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoeae strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.Type: ApplicationFiled: October 30, 2007Publication date: May 29, 2008Applicant: ID BIOMEDICAL CORPORATIONInventors: Bernard R. Brodeur, Denis Martin, Josee Hamel, Clement Rioux
-
Publication number: 20080107675Abstract: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoeae strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.Type: ApplicationFiled: October 30, 2007Publication date: May 8, 2008Applicant: ID BIOMEDICAL CORPORATIONInventors: Bernard Brodeur, Denis Martin, Josee Hamel, Clement Rioux
-
Publication number: 20080107674Abstract: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoeae strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.Type: ApplicationFiled: October 30, 2007Publication date: May 8, 2008Applicant: ID BIOMEDICAL CORPORATIONInventors: Bernard Brodeur, Denis Martin, Josee Hamel, Clement Rioux
-
Publication number: 20080107676Abstract: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoeae strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.Type: ApplicationFiled: October 30, 2007Publication date: May 8, 2008Applicant: ID BIOMEDICAL CORPORATIONInventors: Bernard Brodeur, Denis Martin, Josee Hamel, Clement Rioux
-
Patent number: 7273611Abstract: The identification of a highly conserved, immunologically accessible antigen on the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoaea strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.Type: GrantFiled: October 6, 2000Date of Patent: September 25, 2007Assignee: ID Biomedical CorporationInventors: Bernard R. Brodeur, Denis Martin, Josee Hamel, Clement Rioux
-
Publication number: 20070116712Abstract: Streptococcus proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.Type: ApplicationFiled: August 29, 2006Publication date: May 24, 2007Applicant: ID Biomedical CorporationInventors: Josee Hamel, Bernard Brodeur, Isabelle Pineau, Denis Martin, Clement Rioux, Nathalie Charland
-
Publication number: 20070110766Abstract: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoeae strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.Type: ApplicationFiled: October 16, 2006Publication date: May 17, 2007Applicant: ID Biomedical CorporationInventors: Bernard Brodeur, Denis Martin, Josee Hamel, Clement Rioux
-
Patent number: 7128918Abstract: Streptococcus proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.Type: GrantFiled: December 23, 1999Date of Patent: October 31, 2006Assignee: ID Biomedical CorporationInventors: Josee Hamel, Bernard R. Brodeur, Isabelle Pineau, Denis Martin, Clement Rioux, Nathalie Charland
-
Patent number: 6887686Abstract: Cloning and expression of genes encoding H. somnus transferrin-binding proteins are described. The transferrin-binding proteins can be used in vaccine compositions for the prevention and treatment of H. somnus infections, as well as in diagnostic methods for determining the presence of H. somnus infections.Type: GrantFiled: March 13, 2002Date of Patent: May 3, 2005Assignee: University of SaskatchewanInventors: Andrew A. Potter, Clement Rioux, Anthony B. Schryvers
-
Publication number: 20030228323Abstract: Group B streptococcus (GBS) proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.Type: ApplicationFiled: January 13, 2003Publication date: December 11, 2003Inventors: Bernard R. Brodeur, Clement Rioux, Martine Boyer, Isabelle Charlebois, Josee Hamel, Denis Martin
-
Publication number: 20030044425Abstract: An adjuvant complex composed of bacterial outer membrane protein proteosomes complexed to bacterial liposaccharide is prepared to contain the component parts under a variety of conditions. The complex can be formulated with antigenic material to form immunogenic compositions, vaccines and immunotherapeutics. An induced immune response includes protective antibodies and/or type 1 cytokines is shown for a variety of protocols.Type: ApplicationFiled: March 11, 2002Publication date: March 6, 2003Inventors: David S. Burt, George H. Lowell, Gregory L. White, David Jones, Clement Rioux
-
Publication number: 20030031682Abstract: Group B streptococcus (GBS) proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.Type: ApplicationFiled: February 18, 1999Publication date: February 13, 2003Inventors: BERNARD R. BRODEUR, CLEMENT RIOUX, MARTINE BOYER, ISABELLE CHARLEBOIS, JOSEE HAMEL, DENIS MARTIN